Up to 50% of patients with nrAxSpA can withdraw TNFi and remain in remission

Many patients with non-radiographic axial spondyloarthritis (nrAxSpA ) can successfully withdraw adalimumab treatment if they achieve sustained clinical remission, a randomised controlled trial shows. However not all patients who stop TNF inhibitor treatment and then flare will be able to regain clinical remission, according to results from the ABILITY-3 trial. It is also not possible ...

Already a member?

Login to keep reading.

© 2021 the limbic